
1. j infect dis. 1996 jul;174(1):195-8.

primary infection zidovudine-resistant human immunodeficiency virus type 1
does adversely affect outcome 1 year. sydney primary hiv infection study
group.

imrie a(1), carr a, duncombe c, finlayson r, vizzard j, law m, kaldor j, penny r,
cooper da.

author information: 
(1)centre immunology, st vincent's hospital, sydney, australia.

human immunodeficiency virus type 1 (hiv-1) variants reduced vitro
sensitivity zidovudine, conferred specific mutations viral reverse
transcriptase, emerge prolonged therapy. late-stage disease declining 
cd4 cell count associated rapid emergence resistant
variants. isolates hiv-1 seroconverters screened the
zidovudine-resistance marker mutation codon 215. hiv-1 altered
genotype detected 5 (8.2%) 61 patients soon onset symptomatic 
primary illness sex partner 1 patient. transmitted
resistant viruses either replaced strains susceptible zidovudine
within months infection persisted 1 year absence 
prolonged zidovudine therapy. resistant genotype persisted 3 5
seroconverters 2 patients reverted wild type 48 52 weeks.
primary infection zidovudine-resistant variants hiv-1 associated 
with severe symptomatic primary illness rapid cd4 cell decline 
1 year infection.

doi: 10.1093/infdis/174.1.195 
pmid: 8655994  [indexed medline]

